Johnson & Johnson (JNJ) Updates FY 2019 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.58. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.05 billion.Johnson & Johnson also updated its FY19 guidance to $8.53-8.63 EPS.

NYSE:JNJ opened at $138.02 on Wednesday. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The firm has a market capitalization of $370.29 billion, a P/E ratio of 16.87, a PEG ratio of 2.21 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The business had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. During the same period last year, the business earned $2.06 earnings per share. The firm’s revenue was up .1% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 8.58 EPS for the current year.

Several equities analysts recently weighed in on JNJ shares. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a sell rating in a research note on Tuesday, December 18th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a hold rating in a research note on Thursday, December 20th. Citigroup decreased their target price on shares of Johnson & Johnson from $148.00 to $139.00 and set a neutral rating for the company in a research note on Wednesday, January 2nd. Wells Fargo & Co reaffirmed an outperform rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Barclays reaffirmed an equal weight rating and set a $135.00 price objective (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $143.58.

Hedge funds have recently added to or reduced their stakes in the business. Crewe Advisors LLC boosted its position in Johnson & Johnson by 75.0% during the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after purchasing an additional 150 shares during the period. Ruggie Capital Group boosted its position in shares of Johnson & Johnson by 342.5% in the fourth quarter. Ruggie Capital Group now owns 469 shares of the company’s stock valued at $60,000 after acquiring an additional 363 shares during the period. Litman Gregory Asset Management LLC boosted its position in shares of Johnson & Johnson by 105.9% in the fourth quarter. Litman Gregory Asset Management LLC now owns 486 shares of the company’s stock valued at $63,000 after acquiring an additional 250 shares during the period. Financial Gravity Companies Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $82,000. Finally, Next Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $83,000. 67.32% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Updates FY 2019 Earnings Guidance” was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.modernreaders.com/news/2019/04/17/johnson-johnson-jnj-updates-fy-2019-earnings-guidance.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How to Use the New Google Finance Tool

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.